Quest Diagnostics (DGX) has been active in the biotech market with several noteworthy moves. The company is involved in multiple acquisitions, including purchasing select lab assets from
Allina Health and
PathAI Diagnostics. DGX's earnings and revenue estimates in Q2 and Q4 have outperformed, with the firm also raising full-year guidance for 2024. It has released a robust
Corporate Responsibility Report for 2023. Partnerships have been forged, notably with
Fitbit for a pilot study and a collaboration with
Scipher Medicine to extend precision medicine access for rheumatoid patients. DGX has also ventured into
AI and digital pathology adoption in cancer diagnosis. Some investors are questioning whether it’s appropriate to hold onto the stock at the moment but DGX seems undervalued currently. It has rewarded its shareholders with a quarterly cash dividend. However, some market players like Park Avenue Securities and American International Group have sold shares of DGX.
Quest Diagnostics DGX News Analytics from Tue, 24 Oct 2023 07:00:00 GMT to Sun, 30 Jun 2024 08:46:21 GMT -
Rating 7
- Innovation 4
- Information 6
- Rumor -5
